Clinical Trials
2 trialsNCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated
NCT00101166 2018-02-28
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed